A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Eli Lilly and Company has released promising interim data from its Phase 1b Heart-2 clinical trial, evaluating an investigational in vivo base editing medicine known as VERVE-102. The study, which focuses on patients with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD), suggests that a single intravenous infusion could potentially transform cardiovascular care by shifting the treatment model from chronic daily management to a one-time intervention.
Understanding the Science of VERVE-102
VERVE-102 is engineered to address the root cause of high low-density lipoprotein cholesterol (LDL-C) by targeting the PCSK9 gene in the liver. By utilizing messenger RNA and a guide RNA encapsulated in a lipid nanoparticle, the treatment is designed to durably turn off the gene. This approach mimics the protective effect of naturally occurring genetic variants that have long been associated with a lower lifetime risk of heart disease.
The interim analysis of 35 participants showed that the treatment was well-tolerated across all tested dose levels. Researchers reported no treatment-related serious adverse events or dose-limiting toxicities, with only low-grade infusion-related reactions and fatigue noted among some participants.
Did You Know?
The U.S. Food and Drug Administration has granted Fast Track designation for VERVE-102, a regulatory status intended to facilitate the development and expedite the review of medicines designed to treat serious conditions and fill an unmet medical need.
Clinical Results and Performance
In the Heart-2 trial, a single infusion of the medicine produced dose-dependent reductions in both PCSK9 protein and LDL-C levels. Among the 35 participants, mean reductions in PCSK9 ranged from 51% at the 0.3 mg/kg dose to 88% at the 1.0 mg/kg dose. Corresponding LDL-C reductions were equally significant, reaching up to 62% in the highest dose group.
A critical finding from the study is the durability of these effects. The data indicated that the reductions in LDL-C and PCSK9 were sustained for up to 18 months following the single treatment. This long-term stability is a key focus as investigators continue to monitor the participants, some of whom are expected to remain in a long-term follow-up study for up to 15 years.
Expert Insight:
The potential shift from chronic, lifelong medication to a single-course genetic treatment represents a significant evolution in cardiology. While current therapies often struggle with patient adherence and the burden of daily management, the ability to “turn off” a gene responsible for cardiovascular risk offers a new paradigm for patients who remain at high risk despite existing treatments.
The Path Ahead
Following these positive results, which were presented at the European Atherosclerosis Society (EAS) Congress and published in The New England Journal of Medicine, the next steps for the program are already in motion. Lilly plans to initiate a Phase 2 clinical study of VERVE-102 by the end of this year.
Future studies will likely focus on confirming these initial safety and efficacy findings in a broader population. Because coronary artery disease remains a leading cause of death globally—affecting more than 300 million people—the successful progression of this gene-editing approach could change how clinicians approach lipid-lowering therapies for those with high lifetime cardiovascular risk.
Frequently Asked Questions
What is VERVE-102?
VERVE-102 is an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver to lower LDL-C levels with a single intravenous infusion.
Who is the target population for this treatment?
The Heart-2 trial is evaluating the treatment in adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD) who require additional LDL-C lowering despite current therapies.
How long did the effect of the treatment last in the study?
In this interim analysis, the reductions in both PCSK9 and LDL-C were sustained for up to 18 months following the single infusion.
How might a one-time genetic treatment change the long-term outlook for patients currently managing chronic cardiovascular conditions?